- The FDA has issued an Emergency Use Authorization (EUA) for Becton Dickinson and Co’s (NYSE:BDX) BD Veritor At-Home COVID-19 Test.
- Also Read: BD’s Automated Molecular Diagnostics Platform Wins FDA Approval, Initial Test For HPV
- The at-home COVID-19 rapid antigen test uses computer vision technology in a smartphone to interpret and provide a digital display of testing results.
- It does not require a prescription, a laboratory, or a long wait for results.
- The test will initially be made available to businesses, schools, and governments looking to provide a self-testing option for employees or students.
- The BD Veritor At-Home COVID-19 Test will use a simple, pain-free nasal swab and an easy-to-use mobile app from Scanwell Health that yields reliable test results in 15 minutes.
- The app is available on iOS and Android. The test can also be used for children as young as two years old with samples collected by an adult.
- Related content: Benzinga’s Full FDA Calendar
- Price Action: BDX shares closed 0.35% lower at $247 on Wednesday.
Autohome Anno9unced Haifeng Shao has Stepped Down as Co-President
Autohome Inc. (NYSE: ATHM; HKEX: 2518) ("Autohome" or the "Company"), the leading online destination for automobile consumers in China, today announced that Mr. Haifeng Shao has stepped down from his role as a co-president of the Company due to his other personal commitments. Mr. Shao has no disagreement with the Company.
